Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast ; volume:40 ; number:8 ; day:16 ; month:6 ; year:2023 ; pages:3291-3303 ; date:8.2023
Advances in therapy ; 40, Heft 8 (16.6.2023), 3291-3303, 8.2023
- Urheber
-
Landgren, Ola
Nadeem, Omar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-023-02551-9
- URN
-
urn:nbn:de:101:1-2023101308095555870469
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Landgren, Ola
- Nadeem, Omar
- SpringerLink (Online service)
Ähnliche Objekte (12)
ASH highlights 2022—multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
ASH 2018—Highlights in Multiple Myeloma
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Multiple myeloma: my highlights at ASH 2020
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Bispecific antibodies
Bispecific antibodies
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
ASH highlights 2022—multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
ASH 2018—Highlights in Multiple Myeloma
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Multiple myeloma: my highlights at ASH 2020
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Bispecific antibodies
Bispecific antibodies
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
ASH highlights 2022—multiple myeloma
Bispecific antibodies in the treatment of multiple myeloma
ASH 2018—Highlights in Multiple Myeloma
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Multiple myeloma: my highlights at ASH 2020
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Bispecific antibodies
Bispecific antibodies
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma